Long-acting quinidine bisulphate significantly prolonged the maintenance of sinus rhythm compared to placebo following DC reversion of atrial fibrillation, especially during the first three months.
RCT (n=92)
Double-blind
Random selection
Does long-acting quinidine bisulphate improve the maintenance of sinus rhythm in patients following DC reversion of atrial fibrillation?
Long-acting quinidine bisulphate significantly prolonged the maintenance of sinus rhythm after DC reversion of atrial fibrillation compared to placebo, though it carries a risk of severe toxicity.
Ninety-two patients were entered in a double-blind controlled trial of long-acting quinidine bisulphate for the maintenance of sinus rhythm following DC reversion of atrial fibrillation. By random selection two statistically comparable groups of patients were obtained, a control group being given a placebo and a treated group quinidine bisulphate 1·5 g. per day in two 12-hourly doses. Thirty-seven patients were followed up in the control group and twenty-eight patients in the treated group. The maintenance of sinus rhythm in the treated group was significantly longer than in the control group, especially during the first three months. The mean serum quinidine level in the treated group was 2·2±0·3 (SEM) mg. per litre. There was one death among the patients treated with quinidine, which may have been due to quinidine toxicity caused by a high serum quinidine level.
Byrne-Quinn et al. (Fri,) conducted a rct in Atrial fibrillation (n=92). Long-acting quinidine bisulphate vs. Placebo was evaluated on Maintenance of sinus rhythm. Long-acting quinidine bisulphate significantly prolonged the maintenance of sinus rhythm compared to placebo following DC reversion of atrial fibrillation, especially during the first three months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: